Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2379 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
SPP-037
SPP-037 is an orally active selective inhibitor of ST6GAL1, with an IC50 of 3.59 μM. It exhibits anti-migration activity against MDA-MB-231 cells by inhibiting integrin α2,6-sialylation and the integrin-FAK-paxillin pathway. In MDA-MB-231 xenograft mouse models, SPP-037 demonstrates antitumor properties. This compound is applicable in breast cancer research.Formule :C36H50ClN3O9SCouleur et forme :SolidMasse moléculaire :735.29563DSPE-PEG2000-A7R
DSPE-PEG2000-A7R is a PEG compound consisting of DSPE and a tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, a receptor that is overexpressed in various tumors.Couleur et forme :Odour SolidIBI-334
IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.Couleur et forme :Odour LiquidAnticancer agent 271
Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.Couleur et forme :Odour SolidPST3.1a
CAS :PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).Formule :C32H33O6PCouleur et forme :SolidMasse moléculaire :544.57JH-XI-10-02
CAS :JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formule :C50H55ClFN5O5Couleur et forme :SolidMasse moléculaire :860.45ML228
CAS :ML228 activates HIF pathway and VEGF, with EC50 of 1μM, effective in vitro.Formule :C27H21N5Degré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :415.49JAK-2/3-IN-1
CAS :JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.Formule :C20H12ClN3OCouleur et forme :SolidMasse moléculaire :345.79BTK inhibitor 19
CAS :BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formule :C25H24F3N7O3Couleur et forme :SolidMasse moléculaire :527.508EGFR/COX-2-IN-1
EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.Formule :C20H17FN6O2S2Couleur et forme :SolidMasse moléculaire :456.52Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS :Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.Formule :C88H138N20O34P2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2082.1Varlitinib Tosylate
CAS :Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formule :C36H35ClN6O8S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :811.34TYD-68
TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.Couleur et forme :Odour SolidLewis y tetrasaccharide
CAS :Lewis Y tetrasaccharide, a derivative of Lewis X, is an antigen linked to ovarian cancer metastasis and bad prognosis.Formule :C26H45NO19Couleur et forme :SolidMasse moléculaire :675.63BW710
BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.Formule :C28H29FN6O2SCouleur et forme :SolidMasse moléculaire :532.63SIAIS178
CAS :SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formule :C50H62ClN11O6S2Degré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :1012.68Ref: TM-T12907
1mg152,00€5mg356,00€10mg485,00€25mg888,00€50mg1.431,00€100mg2.052,00€200mg2.673,00€1mL*10mM (DMSO)393,00€VnP-16
VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activatesFormule :C82H112N20O17Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1649.89Amuvatinib hydrochloride
CAS :Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formule :C23H22ClN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.97Antifibrotic agent 1
Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.Formule :C27H23ClN6O2Couleur et forme :SolidMasse moléculaire :498.1571Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Formule :C33H34N4O3Couleur et forme :SolidMasse moléculaire :534.648PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formule :C22H22FN5O2Couleur et forme :SolidMasse moléculaire :407.44SJF 1528
CAS :Potent EGFR & HER2 degrader; DC50 of 39.2 nM in OVCAR8, 736 nM in HeLa; has lapatinib, VHL ligand; inhibits HER2+ breast cancer (IC50=102 nM for SKBr3).Formule :C55H57ClFN7O8SCouleur et forme :SolidMasse moléculaire :1030.61Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Degré de pureté :98%Couleur et forme :Odour SolidEGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Formule :C22H16N4OSCouleur et forme :SolidMasse moléculaire :384.45Pomalidomide-C5-Dovitinib
CAS :Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC that links Pomalidomide and Dovitinib via a CRBN connector, exhibiting potent antiproliferative activity inFormule :C39H38FN9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :747.77AD57
CAS :AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Formule :C22H20F3N7ODegré de pureté :99.05%Couleur et forme :SoildMasse moléculaire :455.44MS9427
CAS :MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.Formule :C48H58ClFN8O12Couleur et forme :SolidMasse moléculaire :993.47VSLRGDTRG acetate
VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.Couleur et forme :Odour SolidBevasiranib sodium
CAS :Bevasiranib sodium, a siRNA, silences genes for VEGF, key in CNV pathogenesis and wet AMD precursor.Couleur et forme :SolidOK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Formule :C42H62N14O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :907.03Axltide
CAS :Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77VEGFR-2-IN-36
VEGFR-2-IN-36 (compound 15) serves as a potent VEGFR-2 inhibitor, exhibiting an IC50 value of 0.067 μM, and acts as an apoptosis inducer with demonstratedFormule :C24H23N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :489.48Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS :Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formule :C51H65N17O19P2S2·xC6H15NCouleur et forme :SolidMasse moléculaire :1447.44DSPE-PEG1000-A7R
DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Couleur et forme :Odour SolidAbl Cytosolic Substrate
CAS :Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Formule :C64H101N15O16Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1336.58PROTAC VEGFR-2 degrader-1
CAS :PROTAC VEGFR-2 degrader-1 shows minimal VEGFR-2 inhibition & low anti-proliferative effect on EA.hy926 cells.Formule :C52H61N9O6SCouleur et forme :SolidMasse moléculaire :940.163-Methylthienyl-carbonyl-JNJ-7706621
CAS :Potent CDK inhibitor 3-Methylthienyl-carbonyl-JNJ-7706621, IC50: CDK1=6.4nM, CDK2=2nM, GSK-3=0.041μM; moderate on CDK4/VEGF-R2/FGF-R2.Formule :C14H14N6O3S2Couleur et forme :SolidMasse moléculaire :378.43FAK-IN-1
CAS :FAK-IN-1 is a FAK inhibitor with anticancer activities (WO2020231726 (Example 27)).Formule :C24H26F3N7O4SCouleur et forme :SolidMasse moléculaire :565.57EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Formule :C27H31N3O2Couleur et forme :SolidMasse moléculaire :429.24163DD 03-171
CAS :Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formule :C55H62N10O8Couleur et forme :SolidMasse moléculaire :991.163EGFR-IN-144
EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.Formule :C20H17Cl2N3O3Couleur et forme :SolidMasse moléculaire :418.273AZ14240475
AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.Formule :C23H15ClF2N6O2Couleur et forme :SolidMasse moléculaire :480.854EGFR-IN-151
EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.Couleur et forme :Odour SolidGefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Formule :C22H24ClFN4O41·5HClCouleur et forme :SolidMasse moléculaire :517.59BCPyr
CAS :BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formule :C58H65F2N11O8Couleur et forme :SolidMasse moléculaire :1082.224PROTAC BTK Degrader-6
CAS :PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expressionFormule :C45H47N11O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :837.92HSK205
HSK205 is a dual FLT3 and haspin inhibitor, exhibiting potent antitumor activity [1], with an IC50 of 0.187 nM for FLT3.Couleur et forme :Odour SolidCS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formule :C45H53F7N12O9Couleur et forme :SolidMasse moléculaire :1038.39467DSPE-PEG2000-GE11
DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.Couleur et forme :Odour Solid
